Mesulergine () (developmental code name CU-32085) is a drug of the ergoline group which was never marketed.
Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) Species 5-HT1A 195–398 Human 5-HT1B 631–1,288 Human 5-HT1D 1,700–>10,000 Human 5-HT1E 5-HT1F >10,000 Human 5-HT2A 19.5–151 Human 5-HT2B 1.44–3.62 Human 5-HT2C 1.12–48.5 Human 5-HT3 >10,000 Rat 5-HT4 5-HT5A 1,000 Rat 5-HT5B 1,000 Rat 5-HT6 776–3,800 Human 5-HT7 7.9–31.6 Human D2 8–12 Rat Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
Mesulergine acts on serotonin and dopamine receptors. Specifically, it is an agonist of dopamine D2-like receptors and serotonin 5-HT6 receptors and an antagonist of serotonin 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors. It also has affinity for the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT5A receptors.National Institute of Mental Health. PDSD Ki Database (Internet). ChapelHill (NC): University of North Carolina. Available from:
Research Mesulergine had entered clinical trials for the treatment of Parkinson's disease; however, further development was halted due to adverse histological abnormalities in rats. It was also investigated for the treatment of hyperprolactinemia (high prolactin levels).
See also Disulergine Etisulergine Quinagolide
References